Peptide Show Transistor (https://transistor.fm) https://feeds.transistor.fm/peptide-show Welcome to the world of Peptides. New episodes every Tuesday. Longr Holdings Inc. beaf18b9-da43-5c7b-8b23-f395d35e38a2 yes Toby Sorabjee Richard Skaife Introducing The Peptide Show en Tue, 08 Sep 2026 05:43:21 -0400 Tue, 08 Sep 2026 05:44:09 -0400 https://longr.io https://img.transistorcdn.com/FpfvZgeWMKzaH4S2bD092RJWyrRG7GSrfDSJ6tVOHYM/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mZTg2/YmYyODMzN2NhMDNh/NzMzZGUxMzJhNDFj/YjVmMS5wbmc.jpg Peptide Show https://longr.io episodic Longr Welcome to the world of Peptides. New episodes every Tuesday. Welcome to the world of Peptides. peptides, peptide therapy, peptide science, peptide medicine, peptide therapeutics, clinical peptides, peptide research, GLP-1, GLP-1 medications, semaglutide, tirzepatide, obesity medicine, metabolic health, longevity medicine, regenerative medicine, health optimization, biohacking, compounding pharmacy, pharmacy compounding, 503A, 503B, FDA, peptide regulation, peptide manufacturing, GMP peptides, peptide synthesis, peptide supply chain, biotech, life sciences, biotech investing, healthcare investing Toby Sorabjee toby@longr.io No No Dr Terry Dubrow: Peptides are about to change everything. Are we ready? 1 1 Dr Terry Dubrow: Peptides are about to change everything. Are we ready? full 8c1ceee7-cd37-44fe-b673-d7ccd4fd99a9 https://share.transistor.fm/s/7dec4084 What happens when millions of people want drugs their doctors can’t prescribe?

Very few doctors become household names. Dr Terry Dubrow is one of them.

For more than two decades, the board-certified plastic surgeon and star of Botched has sat at the intersection of medicine and popular culture, becoming one of the most recognizable doctors in America.

Then peptides changed the direction of his career.

Decades into an already established surgical career, Dr Dubrow went back to study, became board-certified in obesity medicine, and developed what he describes as an obsession with peptides, longevity and what could become the next frontier of medicine. 

He believes peptides could transform healthcare. But as unapproved compounds move online, patients bypass doctors and regulation struggles to keep pace, he is warning that the same revolution could also produce a serious medical backlash. 


He explains:

■ Why GLP-1s changed the direction of his career and pulled him into peptide medicine 
■ Why he believes peptides could eventually change how we age
■ Why retatrutide is already being accessed before FDA approval 
■ Why pushing peptides outside the medical system could make them more dangerous, not less
■ The peptide safety event he fears could trigger a major backlash

Chapters

  • (00:00) - Intro
  • (02:07) - From GLP-1s to peptides
  • (05:07) - Can peptides reverse aging?
  • (07:54) - Peptides and the regulatory Wild West
  • (09:59) - Retatrutide and the next GLP-1s
  • (14:00) - Microdosing GLP-1s for longevity
  • (16:14) - The biggest myths about peptides
  • (18:12) - Why doctors need better peptide data
  • (19:57) - The danger of unregulated peptides
  • (21:52) - The future of peptides and longevity
 

Watch the full episode on YouTube
 

Further reading

FDA: July 2026 Pharmacy Compounding Advisory Committee meeting covering BPC-157, TB-500, MOTS-c and other peptide-related bulk substances: FDA PCAC July 2026 meeting

ClinicalTrials.gov: Phase 3 TRIUMPH-1 study of retatrutide in obesity and overweight: Retatrutide TRIUMPH-1 trial

Read the full transcript
 

Follow Dr Terry Dubrow

Instagram: Instagram.com/drdubrow
X: x.com/DrDubrow
Website: DrDubrow.com

Follow Richard Skaife

LinkedIn: https://www.linkedin.com/in/richardskaife/

The Peptide Show

Website: Peptide.Show

The Peptide Show explores the science, medicine, business and people shaping the rapidly evolving world of peptides.

Presented by Longr: longr.io

Follow The Peptide Show for new episodes every Tuesday.

This podcast is for informational and educational purposes only and does not constitute medical advice. Some compounds discussed in this episode are investigational, unapproved for the uses discussed, or subject to changing regulatory requirements.

]]> What happens when millions of people want drugs their doctors can’t prescribe?

Very few doctors become household names. Dr Terry Dubrow is one of them.

For more than two decades, the board-certified plastic surgeon and star of Botched has sat at the intersection of medicine and popular culture, becoming one of the most recognizable doctors in America.

Then peptides changed the direction of his career.

Decades into an already established surgical career, Dr Dubrow went back to study, became board-certified in obesity medicine, and developed what he describes as an obsession with peptides, longevity and what could become the next frontier of medicine. 

He believes peptides could transform healthcare. But as unapproved compounds move online, patients bypass doctors and regulation struggles to keep pace, he is warning that the same revolution could also produce a serious medical backlash. 


He explains:

■ Why GLP-1s changed the direction of his career and pulled him into peptide medicine 
■ Why he believes peptides could eventually change how we age
■ Why retatrutide is already being accessed before FDA approval 
■ Why pushing peptides outside the medical system could make them more dangerous, not less
■ The peptide safety event he fears could trigger a major backlash

Chapters

  • (00:00) - Intro
  • (02:07) - From GLP-1s to peptides
  • (05:07) - Can peptides reverse aging?
  • (07:54) - Peptides and the regulatory Wild West
  • (09:59) - Retatrutide and the next GLP-1s
  • (14:00) - Microdosing GLP-1s for longevity
  • (16:14) - The biggest myths about peptides
  • (18:12) - Why doctors need better peptide data
  • (19:57) - The danger of unregulated peptides
  • (21:52) - The future of peptides and longevity
 

Watch the full episode on YouTube
 

Further reading

FDA: July 2026 Pharmacy Compounding Advisory Committee meeting covering BPC-157, TB-500, MOTS-c and other peptide-related bulk substances: FDA PCAC July 2026 meeting

ClinicalTrials.gov: Phase 3 TRIUMPH-1 study of retatrutide in obesity and overweight: Retatrutide TRIUMPH-1 trial

Read the full transcript
 

Follow Dr Terry Dubrow

Instagram: Instagram.com/drdubrow
X: x.com/DrDubrow
Website: DrDubrow.com

Follow Richard Skaife

LinkedIn: https://www.linkedin.com/in/richardskaife/

The Peptide Show

Website: Peptide.Show

The Peptide Show explores the science, medicine, business and people shaping the rapidly evolving world of peptides.

Presented by Longr: longr.io

Follow The Peptide Show for new episodes every Tuesday.

This podcast is for informational and educational purposes only and does not constitute medical advice. Some compounds discussed in this episode are investigational, unapproved for the uses discussed, or subject to changing regulatory requirements.

]]> Tue, 08 Sep 2026 01:01:00 -0400 Longr Longr 1421 What happens when millions of people want drugs their doctors can’t prescribe?

Very few doctors become household names. Dr Terry Dubrow is one of them.

For more than two decades, the board-certified plastic surgeon and star of Botched has sat at the intersection of medicine and popular culture, becoming one of the most recognizable doctors in America.

Then peptides changed the direction of his career.

Decades into an already established surgical career, Dr Dubrow went back to study, became board-certified in obesity medicine, and developed what he describes as an obsession with peptides, longevity and what could become the next frontier of medicine. 

He believes peptides could transform healthcare. But as unapproved compounds move online, patients bypass doctors and regulation struggles to keep pace, he is warning that the same revolution could also produce a serious medical backlash. 


He explains:

■ Why GLP-1s changed the direction of his career and pulled him into peptide medicine 
■ Why he believes peptides could eventually change how we age
■ Why retatrutide is already being accessed before FDA approval 
■ Why pushing peptides outside the medical system could make them more dangerous, not less
■ The peptide safety event he fears could trigger a major backlash

Chapters

  • (00:00) - Intro
  • (02:07) - From GLP-1s to peptides
  • (05:07) - Can peptides reverse aging?
  • (07:54) - Peptides and the regulatory Wild West
  • (09:59) - Retatrutide and the next GLP-1s
  • (14:00) - Microdosing GLP-1s for longevity
  • (16:14) - The biggest myths about peptides
  • (18:12) - Why doctors need better peptide data
  • (19:57) - The danger of unregulated peptides
  • (21:52) - The future of peptides and longevity
 

Watch the full episode on YouTube
 

Further reading

FDA: July 2026 Pharmacy Compounding Advisory Committee meeting covering BPC-157, TB-500, MOTS-c and other peptide-related bulk substances: FDA PCAC July 2026 meeting

ClinicalTrials.gov: Phase 3 TRIUMPH-1 study of retatrutide in obesity and overweight: Retatrutide TRIUMPH-1 trial

Read the full transcript
 

Follow Dr Terry Dubrow

Instagram: Instagram.com/drdubrow
X: x.com/DrDubrow
Website: DrDubrow.com

Follow Richard Skaife

LinkedIn: https://www.linkedin.com/in/richardskaife/

The Peptide Show

Website: Peptide.Show

The Peptide Show explores the science, medicine, business and people shaping the rapidly evolving world of peptides.

Presented by Longr: longr.io

Follow The Peptide Show for new episodes every Tuesday.

This podcast is for informational and educational purposes only and does not constitute medical advice. Some compounds discussed in this episode are investigational, unapproved for the uses discussed, or subject to changing regulatory requirements.

]]> Terry Dubrow, Dr Terry Dubrow, Botched, peptides, peptide therapy, GLP-1, retatrutide, obesity medicine, longevity, BPC-157, TB-500, MOTS-c, FDA, peptide regulation No Dr Terry Dubrow Richard Skaife Toby Sorabjee Introducing The Peptide Show Introducing The Peptide Show trailer 1c85dd12-deaf-4e4e-9d03-9d8b39384325 https://share.transistor.fm/s/e431213f The Peptide Show explores the science, medicine and business of peptides, with the people shaping what comes next.

Hosted by Richard Skaife, new episodes arrive every Tuesday.

Episode 1 features Dr Terry Dubrow on peptides, GLP-1s, longevity, regulation and why he believes this field could change medicine.

Presented by Longr.

Follow The Peptide Show so you don't miss the first episode.

]]> The Peptide Show explores the science, medicine and business of peptides, with the people shaping what comes next.

Hosted by Richard Skaife, new episodes arrive every Tuesday.

Episode 1 features Dr Terry Dubrow on peptides, GLP-1s, longevity, regulation and why he believes this field could change medicine.

Presented by Longr.

Follow The Peptide Show so you don't miss the first episode.

]]> Mon, 07 Sep 2026 17:48:35 -0400 Longr Longr 37 The Peptide Show explores the science, medicine and business of peptides, with the people shaping what comes next.

Hosted by Richard Skaife, new episodes arrive every Tuesday.

Episode 1 features Dr Terry Dubrow on peptides, GLP-1s, longevity, regulation and why he believes this field could change medicine.

Presented by Longr.

Follow The Peptide Show so you don't miss the first episode.

]]> peptides, peptide therapy, peptide science, peptide medicine, peptide therapeutics, clinical peptides, peptide research, GLP-1, GLP-1 medications, semaglutide, tirzepatide, obesity medicine, metabolic health, longevity medicine, regenerative medicine, health optimization, biohacking, compounding pharmacy, pharmacy compounding, 503A, 503B, FDA, peptide regulation, peptide manufacturing, GMP peptides, peptide synthesis, peptide supply chain, biotech, life sciences, biotech investing, healthcare investing No Toby Sorabjee Richard Skaife